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Abstract Natural killer (NK) cells require interaction of
inhibitory surface receptors with human leukocyte antigen
(HLA) ligands during development to acquire functional
competence in a process termed “licensing.” The quantity
of HLA required for this process is unknown. Two poly-
morphisms affecting HLA-C surface expression (rs9264942
and rs67384697) have recently been identified, and shown
to influence progression of HIV infection. We typed a cohort
of healthy donors for the two HLA-C-related polymor-
phisms, KIR2DL1 and KIR2DL3, and their respective
HLA-C ligands and analyzed how HLA ligands influenced
licensing status of killer cell immunoglobulin-like receptor
(KIR)+ NK cells in terms of degranulation and cytokine
production in response to HLA-deficient target cells. The
presence of respective HLA class I ligands increased the
function of KIR2DL1+ and KIR2DL3+ NK cells in a dose-
dependent manner. In contrast, neither of the HLA-C-related
polymorphisms nor the quantity of cell surface HLA-C had
any significant effect on NK cell function. Interestingly,
HLA-Cw7—an HLA-C allele with low surface expression—
licensed KIR2DL3+ NK cells more strongly than any other
KIR2DL3 ligand. The quantity of cell surface HLA-C does
not appear to influence licensing of NK cells, and the HLA-C-
related polymorphisms presumably influence HIV progres-
sion through factors unrelated to NK cell education.
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Introduction
Natural killer (NK) cells are a subset of lymphocytes in-
volved in the defense against viral infection and malignant
transformation. Upon target recognition, NK cells synthe-
size and secrete cytokines and lyse target cells without the
need for pre-activation (Lanier 2005). NK cell function is
regulated by the integration of signals derived from activat-
ing and inhibitory receptors. Among inhibitory receptors,
killer cell immunoglobulin-like receptors (KIR)—which
bind to class I human leukocyte antigens (HLA)—play a
pivotal role in discriminating normal from pathologic tissue
(Biassoni et al. 2003). The inhibitory signal derived from
the KIR/HLA interaction renders NK cells tolerant towards
autologous tissue, whereas cells lacking HLA class I may
trigger an NK cell response resulting in target cell lysis.
Recent evidence has pointed out that this function is
acquired during NK cell development in a process termed
“licensing”: only NK cells expressing inhibitory receptors
for self-HLA obtain the functional competence to respond to
the lack of HLA ligands on a target cell (Anfossi et al. 2006;
Kim et al. 2008; Yokoyama and Kim 2006). In contrast, NK
cells whose inhibitory receptors did not interact with their
cognate ligands during development remain unlicensed
(Brodin and Hoglund 2008). A previous study analyzing
the interaction of the KIR3DL1 receptor with its ligand—
HLA with the Bw4 motif—showed that NK cells from
donors carrying two Bw4 alleles showed higher levels of
licensing compared to NK cells from donors carrying no or
only one Bw4 allele (Kim et al. 2008). As a further potential
variable in the equation, HLA antigens are expressed on the
cell surface at varying quantities. A single nucleotide
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polymorphism (SNP; rs9264942) located 35 kb upstream of
the HLA-C gene—termed HLA-C −35—was recently identi-
fied to associate with the abundance of cell surface HLA-C
(Thomas et al. 2009). HLA-C −35 has been demonstrated to
be a major factor governing viral load and progression of
human immunodeficiency virus (HIV) infection. “Set point”
viral load in untreated patients was lower, and progression of
HIV was delayed in patients carrying C alleles—associated
with higher amounts of cell surface HLA-C—compared to
carriers of T alleles (Fellay et al. 2007; Pereyra et al. 2010).
Following this, a novel single nucleotide deletion polymor-
phism in the 3′ untranslated region (UTR) of HLA-C
(rs67384697) has been shown to influence binding of the
microRNA hsa-miR-148, and thereby associated with HLA-
C surface expression (Kulkarni et al. 2011). Similar to HLA-
C −35, this single nucleotide polymorphism was shown to
associate with HIV set point viral loads.
As NK cells participate in the control of HIV replication
(Alter et al. 2011), we hypothesized that the association of
HLA-C −35 and the 3′ UTR HLA-C deletion SNP with HIV
progression might be due to a role for the quantity of HLA-C
in the NK cell licensing process. To address the question
experimentally, we assessed in a large cohort of healthy
donors both HLA-C-related polymorphisms and HLA-C sur-
face expression on lymphocytes. We correlated these data to
the functional competence of NK cells in terms of cytokine
production and degranulation after exposure to class I nega-
tive tumor cells. NK cell function was compared in NK cell
subsets with or without expression of the inhibitory KIR
receptors KIR2DL1 and KIR2DL3, which recognize mutually
exclusive subsets of HLA-C ligands termed C1 and C2
(Winter et al. 1998). The HLA C1 group includes HLA Cw
antigens carrying asparagine at position 80 (e.g., HLA Cw1,
Cw3, Cw7, and Cw8), whereas the HLA C2 group includes
HLA Cw antigens carrying lysine at position 80 (e.g., HLA
Cw2, Cw4, Cw5, and Cw6; Winter and Long 1997).
Materials and methods
Antibodies and flow cytometry
The following mAbs were used: anti-CD3 Pacific blue
(OKT3, eBioscience), anti-CD56 PE-Cy7 (HCD56, Biole-
gend), anti-CD107a PE (clone H4A3, BD), anti-IFN-γ PE
(clone B27, BD), anti-KIR2DL1 FITC (clone 143211, R&D),
anti-KIR2DL3 APC (clone 180701, R&D), and the pan-
HLA-C antibody DT9 (kindly provided by Mary Carrington,
National Institute of Health, Bethesda, USA) which was used
in conjunction with goat anti-mouse IgG2b PE (Southern
Biotech).
To evaluate HLA-C surface expression, we used Quan-
tumTM R-PE MESF Kit (Polysciences, Inc., Warrington,
USA) according to the manufacturer’s instructions. The
mean fluorescence intensity of the five bead populations
was used to calculate a calibration curve by plotting the
MFI for each population against its known units of mole-
cules of equivalent soluble fluorophores (MESF). Staining
intensity of DT9 is therefore expressed as MESF units.
Samples were acquired on a DAKO CyAn ADP nine-
color flow cytometer (Beckman Coulter). For all analyses of
NK cell subsets, we gated on the CD56+/CD3− subset. For
quantification of HLA-C expression, we gated on total lym-
phocytes. Fluorescence-activated cell sorting (FACS) plots
were analyzed with FlowJo software version 9.2.
CD107a and IFN-γ assay
Peripheral blood mononuclear cells (PBMCs) from healthy
donors were collected under an ethical committee-approved
protocol, isolated by density gradient centrifugation, and
cryopreserved. After thawing, cells were cultured overnight
in the presence of 150 U/mL recombinant human IL-2
(Proleukin, Novartis), after which PBMCs (0.5×10e6) were
mixed with the HLA-deficient 721.221 cell line at a ratio of
5:1 in a final volume of 200 μL in flat-bottom 96-well plates
and incubated for 5 h at 37 °C/5 % CO2. NK cell response to
721.221 was measured in terms of degranulation (CD107a
surface expression) and cytokine production (intracellular
cytokine staining for IFN-γ; Alter et al. 2004).
Anti-CD107a PE was added to wells at the beginning of
the incubation. For the IFN-γ assay, brefeldin A (Golgi
Plug, BD Biosciences) was added after 1 h of incubation
at a concentration of 1:200, after which cells remained
incubated for another 4 h. For intracellular staining of
IFN-γ, cells were permeabilized with Cytofix/Cytoperm
(BD) and washed with BD Perm/Wash buffer. As positive
control, phorbol 12-myristate 13-acetate, and a calcium
ionophore (ionomycin) were used.
To assess the magnitude of licensing conferred by
KIR2DL1 and KIR2DL3, frequencies of IFN-γ+ and
CD107a+ cells were assessed in CD56+/CD3−/KIR+ and
CD56+/CD3−/KIR− subsets. Ratios of IFN-γ+ cells and
CD107a + cells within KIR+ and KIR− NK cells were
calculated to estimate the alteration in functional compe-
tence derived by the expression of the respective KIR re-
ceptor (Fig. 1). We then compared the effect of the presence
or absence of HLA C1/C2 group ligands, the HLA-C −35
and 3′ UTR HLA-C polymorphisms, and the amount of cell
surface HLA-C had on these licensing ratios.
Genotyping and quantitative PCR
The HLA-C −35 SNP was genotyped using a commercial
ABI TaqMan allelic discrimination kit on the ABI7500
Sequence Detection System according to manufacturer's
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guidelines. The rs67384697 polymorphism located within
the 3′ UTR was typed by direct sequencing (Kulkarni et al.
2011). Genotyping for HLA-C1/C2 group KIR ligands and
for the inhibitory KIR2DL1 and KIR2DL3 was performed
using previously established sequence-specific primer pro-
tocols (Alves et al. 2009; Frohn et al. 1998). HLA-C was
Fig. 2 Degranulation and cytokine production of KIR2DL1+ and
KIR2DL3 NK+ cells in relation to the number of KIR ligands.
CD107a and IFN expression are evaluated in NK cells derived from
66 donors after co-incubation with the HLA-deficient 721.221 cell line.
CD107a expression and IFN-γ production of KIR2DL1+ NK cells
significantly increase with growing numbers of C2 ligands (a and b).
CD107a expression and IFN-γ production of KIR2DL3+ NK cells
significantly increase with growing number of C1 ligands (c and d)
Fig. 3 Correlation of degranulation and cytokine production of
KIR2DL1 and KIR2DL3 NK subsets with the HLA-C −35 polymor-
phism. The HLA-C −35 genotype does not significantly influence NK
licensing of KIR2DL1+ and KIR2DL3+ NK cells as assessed by
CD107a expression and IFN-γ production after exposure to the HLA
class I-negative cell line 721.221
Fig. 1 Increased functional
capacity of NK cells expressing
inhibitory KIR2D receptors.
After gating on CD56+/CD3−
NK cells, CD107a expression
induced by co-incubation with
721.221 tumor cells is compared
in NK cells which do or do not
carry the inhibitory KIR2DL1
receptor. The ratio of CD107a
expression in KIR2DL1+ and
KIR2DL1− NK cells (termed
“licensing ratio”) quantifies the
increase in functional compe-
tence derived from expression
of KIR2DL1. IFN-γ production
and the receptor KIR2DL3
were analyzed in the
same fashion
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typed by applying a reverse sequence-specific oligonucleo-
tide method according to the manufacturer’s instructions
(One Lambda Inc., Canoga Park, CA).
Statistics
Functional and phenotypic NK cell-related characteristics
were compared with nonparametric tests (Mann–Whitney
U and Kruskal–Wallis). Correlations were assessed by cal-
culating Spearman’s rank correlation coefficient. Factors
affecting NK cell function were analyzed in a multivariable
fashion using generalized linear models. All p values are
two-sided and were considered significant if ≤0.05.
Results
Function of KIR2DL1+ and KIR2DL3+ NK cells
is regulated by the number of HLA-C KIR ligands
Phenotypic and functional characteristics of 66 healthy donors
were analyzed. At the HLA-C locus, 20 donors (30 %) were
homozygous for C1 (C1C1), 15 donors were homozygous for
C2 (C2C2), and the remaining 31 donors were heterozygous
(C1C2). All donors in this study carried and expressed the
KIR2DL1 gene, and eight donors were negative for KIR2DL3
and were excluded from the analyses focusing on this
receptor.
Fig. 4 Correlation of HLA-C
expression HLA-C −35 geno-
type and NK cell function. The
HLA-C −35 genotype influences
the expression of HLA-C as
detected by the DT9 antibody in
flow cytometry (panel a). A
trend towards higher expression
of HLA-C is detected for patients
carrying the deletetion variant in
the 3’UTR of HLA-C (panel b).
In contrast, no significant corre-
lation was detected between
CD107a licensing ratios (panel
c) and IFN-γ licensing ratios
(panel d), respectively, and sur-
face expression of HLA-C
Table 1 Multivariate analysis of factors influencing licensing of KIR2D expressing NK cells
CD107a IFN-γ
Effect size 95 % CI p value Effect size 95 % CI p value
Number of HLA-C ligands +0.17 +0.07 to +0.26 0.001 +0.17 +0.08 to +0.26 <0.001
HLA-C (increase per 10,000 MESF) −0.002 −0.02 to +0.02 0.85 −0.01 −0.04 to +0.01 0.26
HLA-C −35
TT 0.00 – – 0.00 – –
CT −0.01 −0.15 to +0.14 0.95 −0.07 −0.22 to +0.08 0.37
CC −0.03 −0.22 to +0.17 0.78 −0.04 −0.24 to +0.17 0.71
3′ UTR SNP
Non-del/non-del 0.00 – – 0.00 – –
Non-del/del +0.01 −0.01 to +0.19 0.95 −0.03 −0.37 to +0.25 0.70
Del/del +0.07 −0.09 to +0.22 0.40 −0.06 −0.21 to +0.15 0.77
742 Immunogenetics (2012) 64:739–745
Analysis of NK cell function in correlation with KIR ligand
status confirmed and extended previously published data on
the functional consequence of co-expression of the inhibitory
KIR3DL1with its ligand, HLAwith the Bw4motif (Kim et al.
2008). Both cytokine production and degranulation signifi-
cantly increased in NK cells carrying inhibitory KIR2D with
HLA-C specificity if the corresponding ligand was present
(Fig. 2). KIR2DL1-positive NK cells produced more cytokine
and degranulated at higher frequency in donors carrying one
or two copies of the KIR2DL1 ligand HLA group C2 (Fig. 2a,
b). In contrast, NK cells expressing KIR2DL3 were most
functional in donors carrying the C1 group ligand for this
receptor (Fig. 2c, d).
HLA-C-related polymorphisms and quantity of HLA-C
do not correlate with NK cell function
At the HLA-C −35 SNP locus, 12 donors (18 %) carried two
C alleles (CC), 22 donors (33 %) carried two T alleles (TT),
and the remaining 32 donors (49 %) were heterozygous
(CT). In univariate analysis, no difference in CD107a ex-
pression and IFN-γ production of KIR2DL1+ and
KIR2DL3+ NK cell subsets were detected between CC,
CT, or TT donors (Fig. 3).
We next evaluated HLA-C surface expression with the
pan-HLA-C antibody DT9 on lymphoid cells by FACS. In
agreement with published data (Thomas et al. 2009), we
found a significant correlation between HLA-C −35 poly-
morphism and HLA-C surface expression (Fig. 4a). As
expected, correlation of HLA-C surface expression with
the 3′ UTR SNP showed a trend towards higher surface
HLA-C for carriers of the deleted variant; however, this
correlation did not reach the level of statistical significance
(Fig. 4b). As the quantity of surface HLA-C might affect the
licensing process independently from the HLA-C −35 and 3′
UTR SNP status, we next correlated NK cell licensing ratios
to surface HLA-C quantity. Neither licensing ratios of
CD107a degranulation nor IFN-γ cytokine production was
significantly correlated to DT9 expression (r2 0.001, p00.77
for CD107a, Fig. 4c; r200.01, p00.24 for IFN-γ, Fig. 4d).
Finally, we used multivariable generalized linear models
to account for potential confounding between variables in-
fluencing licensing status. Table 1 shows the results of the
analysis accounting for number of HLA-C ligands, HLA-C
quantity (DT9 expression), and the HLA-C-related poly-
morphisms. The only variable significantly influencing NK
cell licensing by KIR2DL1 and KIR2DL3 was the number
of HLA-C ligands, whereas both HLA-C-related polymor-
phisms and HLA-C quantity failed to significantly impact
NK cell licensing.
HLA-Cw7 strongly licenses KIR2DL3+ NK cells
despite being expressed at low quantities at the cell
surface
A previous study by Corrah et al. investigating the relation-
ship between HLA-C −35 and cell surface HLA-C described
low surface expression of HLA-Cw7, but failed to replicate a
correlation of HLA-C −35 status with surface HLA-C regard-
ing alleles other than Cw7 (Corrah et al. 2011). We therefore
performed HLA-C typing on our cohort, which revealed that
20 donors (30 %) carried one Cw7 allele, and an additional 3
donors (5 %) carried two HLA-Cw7 alleles (in all cases either
Cw*0701 or Cw*0702, which are both in linkage disequilib-
rium with HLA-C −35T). Correlation of Cw7 status with cell
surface HLA-C quantity showed a dose-dependent reduction
of HLA-C quantity with increasing number of HLA-Cw7
alleles (Fig. 5a), thus confirming the data by Corrah et al..
Also in agreement with this study, we found that after exclu-
sion of donors carrying HLA-Cw7 alleles, the HLA-C −35
status no longer significantly affected the HLA-C cell surface
expression (median MESF 78590, 77797, and 74665, for CC,
CT, and TT donors, respectively, p00.65).
Despite being expressed at low quantity, HLA-Cw7
proved to strongly license KIR2DL3+ NK cells (Fig. 5b,
c). With an average increase per Cw7 ligand in the
Fig. 5 Correlation of HLA-Cw7 status and cell surface HLA-C quan-
tity and NK cell function. HLA-C surface expression—as measured
with the pan-HLA-C antibody DT9—progressively decreases in
donors carrying 0, 1, or 2 HLA-Cw7 alleles (a). Despite low surface
expression, HLC-Cw7 strongly licenses KIR2DL3+ NK cells as
assessed by CD107a and IFN-γ production (b and c)
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KIR2DL3 licensing ratios of +0.17 for CD107a and +0.19
for IFN-γ (p00.02 and <0.001), Cw7 licensed KIR2DL3
more strongly than other frequently expressed group C1
ligands: Cw1 +0.12/+0.07; Cw3 +0.08/+0.10, Cw8 0.09/
+0.12 (for CD107a and IFN-γ, respectively). The strongest
KIR2DL1-licensing ligand was HLA-Cw5 (+0.24/+0.22 for
CD107a and IFN-γ, respectively).
Discussion
In the present study, we addressed a potential impact of the
surface expression quantity of HLA-C on NK cell licensing.
We chose to study licensing by KIR2DL1 and KIR2DL3
because these receptors have defined and mutually exclusive
ligands and because antibodies to both receptors are available
which do not cross-react with the respective counterpart acti-
vating KIR. In agreement with previous studies (Anfossi et al.
2006), we show that the HLA-C-specific inhibitory receptors
KIR2DL1 and KIR2DL3 confer increased functional capacity
to NK cells in donors that carry the respective KIR ligands.
Both IFN-γ production and degranulation dose-dependently
increased with the number of KIR ligands in NK cells express-
ing KIR2DL1 and KIR2DL3.
No statistically significant effect onNK cell licensing could
be attributed to theHLA-C −35, the 3′UTR HLA-C polymor-
phism, or the amount of cell surface HLA-C. One possible
explanation for the failure of cell surface HLA to influence the
licensing process is that the threshold quantity required for
NK cell licensing lies below the level of even low-expressing
alleles. Recent studies have estimated the number of HLA-C
molecules necessary to inhibit NK cell activation via interac-
tion with KIR2DL1 receptor. These analyses have suggested
that inhibition increases with growing number of HLA-C
molecules with a saturation threshold at approximately
20,000 molecules/cell, above which inhibition reaches a pla-
teau (Almeida et al. 2011). It is conceivable that a similar
threshold exists for the KIR/HLA interaction during the li-
censing process, and that even low-expressing alleles are
expressed at quantities above this threshold.
In agreement with previous data (Thomas et al. 2009), we
found a significant correlation ofHLA-C −35with the amount
of HLA-C as measured by flow cytometry. Another recently
published study only partially confirmed the association of
HLA-C −35with cell surface HLA-C. Corrah et al. showed in
their analysis of 25 HIV-infected patients that the correlation
of HLA-C −35 with cell surface HLA-C quantity was exclu-
sively due to the linkage disequilibrium of HLA-Cw7 with
HLA-C −35T (Corrah et al. 2011). In our population of
healthy donors, we confirm that Cw7 shows significantly
lower surface expression than non-Cw7 alleles, but unexpect-
edly found that HLA-Cw7 more strongly licenses KIR2DL3+
NK cells than any other C1 group ligand. These data are in
agreement with the notion that allelic polymorphism within
HLA-C rather than quantity of cell surface expression influ-
ences the NK cell licensing process.
An issue that remains unresolved by this study is how
homozygosity for class I KIR ligands increases licensing
(Elliott and Yokoyama 2011). KIR ligand homozygosity is
expected to increase the number of HLA molecules expressed
on a cell, but the data shown here suggest that the resulting
increased effector capacity might not be due to an increase in
quantity of KIR ligands alone. Interestingly, many studies in
humans have shown that homozygous presence of KIR ligands
is necessary to see licensing effects (Khakoo et al. 2004; Kim
et al. 2008), whereas in mouse models heterozygous for the
major histocompatibility complex (MHC)-I ligand for a given
Ly49 receptor, licensing could be documented (Jonsson et al.
2010). So far, it remains open whether licensing in humans and
in mice is differentially regulated regarding the requirement of
MHC-I ligand zygosity.
In conclusion, we found no evidence that the HLA-C-
related polymorphisms or quantity of cell surface HLA-C
regulates the NK cell licensing process. Regarding the asso-
ciation ofHLA-C −35 and of the 3′ UTR SNP with the course
of HIV infection, our data do not support a role of NK cell
licensing in the improved disease control of carriers of HLA-C
−35 C alleles or 3′ UTR deletion variants. However, a major
limitation of this study lies in the facts that experiments were
carried out with NK cells derived from healthy donors rather
than HIV patients. Chronic HIV infection leads to profound
changes in NK cell phenotype and function (Mavilio et al.
2003), which might also affect the licensing process. Alterna-
tive explanations to be investigated in the future include an
association of HLA-C −35 and of 3′ UTR deletion variants
with HLA-C alleles endowed with increased function regard-
ing their interaction with CD8+ Tcells, or associations that are
completely independent from HLA-C surface expression.
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